{
    "nctId": "NCT02528383",
    "briefTitle": "Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors",
    "officialTitle": "Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors: Systemic Impact Versus Local Objective Benefits and Quality of Life",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 3,
    "primaryOutcomeMeasure": "Changes in serum estrogen levels",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Treatment of Urogenital symptoms with Vagifem, as deemed appropriate by the treating physician\n2. History of breast cancer stages 0-III\n3. Currently being treated with Aromatase Inhibitors (brand not restrictive) for 3 months or longer\n4. Postmenopausal women including those with medically induced menopause\n5. Urogenital symptoms consistent with vaginal atrophy.\n6. Age 18 years or greater\n7. Able to participate in informed consent process\n8. Able to read/speak English\n9. Able to take daily doses of Vitamin D and Calcium\n\nExclusion Criteria:\n\n1. Abnormal or unexplained uterine bleeding\n2. Unable to give informed consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}